THE LATEST APPROACHES TO DYSLIPIDEMIA MANAGEMENT. A NARRATIVE REVIEW
DOI:
https://doi.org/10.31435/ijitss.2(50).2026.5647Keywords:
Dyslipidemia, Hypercholesterolemia, Familial Hypercholesterolemia, Statins, Cardiovascular DiseaseAbstract
Dyslipidemia is a significant, modifiable contributor to cardiovascular disease (CVD), exhibiting significant global prevalence and imposing a particularly high burden in Europe and around the world. Although statins are widely prescribed, a considerable proportion of patients do not achieve lipid targets or experience intolerance, highlighting the need for novel therapeutic strategies. This narrative review examines emerging therapeutic approaches that extend beyond conventional lipid-lowering agents(Cannon, 2022). The paper was prepared based on a review of the literature, with primary emphasis on studies published within the past five years and focused on providing a more detailed presentation of the following therapeutic approaches.
Bempedoic acid, an oral ATP-citrate lyase inhibitor, achieves effective LDL-C reduction with a favourable safety profile, particularly among statin-intolerant patients, and is associated with improved cardiovascular outcomes. Inhibition of angiopoietin-like protein 3 (ANGPTL3) offers a receptor-independent mechanism that results in substantial reductions in LDL-C and triglycerides, particularly in refractory conditions such as homozygous familial hypercholesterolemia. RNA-based therapies, including small interfering RNA (siRNA), provide highly specific and durable gene silencing, as demonstrated by inclisiran and other emerging agents targeting APOC3, ANGPTL3, and lipoprotein(a); infrequent dosing regimens may further enhance adherence.
Gene therapy and genome editing technologies, including CRISPR-based methods, represent a transformative paradigm with the potential to achieve long-term or permanent correction of dyslipidemia. Collectively, these innovations expand therapeutic options, address residual cardiovascular risk, and advance lipid management toward precision and potentially curative strategies.
References
Banach, M., Penson, P. E., Farnier, M., Fras, Z., Latkovskis, G., Laufs, U., Paneni, F., Parini, P., Pirro, M., Reiner, Ž., Vrablik, M., & Escobar, C. (2023). Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP). Progress in Cardiovascular Diseases, 79, 2–11. https://doi.org/10.1016/j.pcad.2023.03.001
Brandts, J., & Ray, K. K. (2021). Familial hypercholesterolemia: JACC focus seminar 4/4. Journal of the American College of Cardiology, 78(18), 1831–1843. https://doi.org/10.1016/j.jacc.2021.09.004
Cannon, C. P. (2022). Statin intolerance: How common is it and how do we work with patients to overcome it? European Heart Journal, 43(34), 3224–3226. https://doi.org/10.1093/eurheartj/ehac156
Carugo, S., Sirtori, C. R., Gelpi, G., Corsini, A., Tokgozoglu, L., & Ruscica, M. (2023a). Updates in small interfering RNA for the treatment of dyslipidemias. Current Atherosclerosis Reports, 25(11), 805–817. https://doi.org/10.1007/s11883-023-01156-5
Carugo, S., Sirtori, C. R., Gelpi, G., Corsini, A., Tokgozoglu, L., & Ruscica, M. (2023b). Updates in small interfering RNA for the treatment of dyslipidemias. Current Atherosclerosis Reports, 25(11), 805–817. https://doi.org/10.1007/s11883-023-01156-5
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., Leader, J. B., Murray, M. F., Ritchie, M. D., Kirchner, H. L., Habegger, L., Lopez, A., Penn, J., Zhao, A., Shao, W., … Baras, A. (2017). Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. New England Journal of Medicine, 377(3), 211–221. https://doi.org/10.1056/nejmoa1612790
Drexel, H., & Mader, A. (2024). Bempedoic acid: How will it shape the future lipid-lowering landscape? Mode of action, evidence, and clinical use. Cardiology (Switzerland), 149(1), 71–77. https://doi.org/10.1159/000535372
Gao, Y., Bai, Y., Mu, X., & Pang, X. (2026). Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: An updated systematic review and meta-analysis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1736821
Geladari, E., Tsamadia, P., & Vallianou, N. G. (2019). ANGPTL3 inhibitors: Their role in cardiovascular disease through regulation of lipid metabolism. Circulation Journal, 83(2), 267–273. https://doi.org/10.1253/circj.CJ-18-0442
Gurevitz, C., Bajaj, A., Khera, A. V., Do, R., Schunkert, H., Musunuru, K., & Rosenson, R. S. (2025). Gene therapy and genome editing for lipoprotein disorders. European Heart Journal, 46(35), 3420–3433. https://doi.org/10.1093/eurheartj/ehaf411
Hoekstra, M., & Van Eck, M. (2024). Gene editing for the treatment of hypercholesterolemia. Current Atherosclerosis Reports, 26(5), 139–146. https://doi.org/10.1007/s11883-024-01198-3
Katzmann, J. L., Packard, C. J., Chapman, M. J., Katzmann, I., & Laufs, U. (2020). Targeting RNA with antisense oligonucleotides and small interfering RNA: JACC state-of-the-art review. Journal of the American College of Cardiology, 76(5), 563–579. https://doi.org/10.1016/j.jacc.2020.05.070
Nissen, S. E., Lincoff, A. M., Brennan, D., Ray, K. K., Mason, D., Kastelein, J. J. P., Thompson, P. D., Libby, P., Cho, L., Plutzky, J., Bays, H. E., Moriarty, P. M., Menon, V., Grobbee, D. E., Louie, M. J., Chen, C.-F., Li, N., Bloedon, L., Robinson, P., … Nicholls, S. J. (2023). Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. New England Journal of Medicine, 388(15), 1353–1364. https://doi.org/10.1056/nejmoa2215024
Pirillo, A., Casula, M., Olmastroni, E., Norata, G. D., & Catapano, A. L. (2021). Global epidemiology of dyslipidaemias. Nature Reviews Cardiology, 18(10), 689–700. https://doi.org/10.1038/s41569-021-00541-4
Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M. (2019). Safety and efficacy of bempedoic acid to reduce LDL cholesterol. New England Journal of Medicine, 380(11), 1022–1032. https://doi.org/10.1056/nejmoa1803917
Ray, K. K., Ference, B. A., Séverin, T., Blom, D., Nicholls, S. J., Shiba, M. H., Almahmeed, W., Alonso, R., Daccord, M., Ezhov, M., Olmo, R. F., Jankowski, P., Lanas, F., Mehta, R., Puri, R., Wong, N. D., Wood, D., Zhao, D., Gidding, S. S., … Santos, R. D. (2022). World Heart Federation cholesterol roadmap 2022. Global Heart, 17(1). https://doi.org/10.5334/GH.1154
Ray, K. K., Oru, E., Rosenson, R. S., Jones, J., Ma, X., Walgren, J., Haupt, A., Verma, S., Gaudet, D., Nicholls, S. J., & Ruotolo, G. (2025). Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): A double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet, 405(10489), 1594–1607. https://doi.org/10.1016/S0140-6736(25)00507-0
Rosenson, R. S., Burgess, L. J., Ebenbichler, C. F., Baum, S. J., Stroes, E. S. G., Ali, S., Khilla, N., Hamlin, R., Pordy, R., Dong, Y., Son, V., & Gaudet, D. (2020). Evinacumab in patients with refractory hypercholesterolemia. New England Journal of Medicine, 383(24), 2307–2319. https://doi.org/10.1056/nejmoa2031049
Rosenson, R. S., Shaik, A., & Song, W. (2021). New therapies for lowering triglyceride-rich lipoproteins: JACC focus seminar 3/4. Journal of the American College of Cardiology, 78(18), 1817–1830. https://doi.org/10.1016/j.jacc.2021.08.051
Ruscica, M., Sirtori, C. R., Carugo, S., Banach, M., & Corsini, A. (2022). Bempedoic acid: For whom and when. Current Atherosclerosis Reports, 24(10), 791–801. https://doi.org/10.1007/s11883-022-01054-2
Soffer, D., Stoekenbroek, R., & Plakogiannis, R. (2022). Small interfering ribonucleic acid for cholesterol lowering – Inclisiran: Inclisiran for cholesterol lowering. Journal of Clinical Lipidology, 16(5), 574–582. https://doi.org/10.1016/j.jacl.2022.06.009
Stankov, S., & Cuchel, M. (2023a). Gene editing for dyslipidemias: New tools to “cut” lipids. Atherosclerosis, 368, 14–24. https://doi.org/10.1016/j.atherosclerosis.2023.01.010
Stankov, S., & Cuchel, M. (2023b). Gene editing for dyslipidemias: New tools to “cut” lipids. Atherosclerosis, 368, 14–24. https://doi.org/10.1016/j.atherosclerosis.2023.01.010
Zdrojewski, T., Rutkowski, M., Bandosz, P., Gaciong, Z., Jedrzejczyk, T., Solnica, B., Pencina, M., Drygas, W., Wojtyniak, B., Grodzicki, T., Piwoński, J., & Wyrzykowski, B. (2013). Prevalence and control of cardiovascular risk factors in Poland. Assumptions and objectives of the NATPOL 2011 Survey. Kardiologia Polska, 71(4), 381–392. https://doi.org/10.5603/KP.2013.0066
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Sonia Pawełkiewicz, Kinga Łysak , Kornelia Julia Fimiarz , Irmina Grygutis , Urszula Jarzęcka , Aleksandra Suchołbiak , Filip Lachowski , Maja Kozielec, Kaja Kozielec, Joanna Górak
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
